Journal of Neurology

, Volume 255, Issue 4, pp 567–574

Volumetric MRI and cognitive measures in Alzheimer disease

Comparison of markers of progression
  • B. H. Ridha
  • V. M. Anderson
  • J. Barnes
  • R. G. Boyes
  • S. L. Price
  • M. N. Rossor
  • J. L. Whitwell
  • L. Jenkins
  • R. S. Black
  • M. Grundman
  • N. C. Fox
ORIGINAL COMMUNICATION

Abstract

Background

Both cognitive tests and MRI-based measures have been suggested as outcomes in trials assessing disease-modifying therapies in Alzheimer's disease (AD).

Objective

To compare changes in longitudinal MRI measures with changes in performance on cognitive tests routinely used in AD clinical trials.

Method

Fifty-two subjects from the placebo-arm of a clinical trial in mild-to-moderate AD had volumetric T1-weighted scans and cognitive tests including the Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale, Disability Assessment for Dementia, AD Cooperative Study-Clinical Global Impression of Change and Clinical Dementia Rating at baseline and one-year later. Rates of brain atrophy and ventricular enlargement were measured using the boundary shift integral. Hippocampal (Hc) atrophy was calculated from manual volume measurements. The relationships between MRI and cognitive measures were investigated.

Results

Rates of brain atrophy and/or ventricular enlargement were correlated with declining performance on cognitive scales. The strongest association was between brain atrophy rate and MMSE decline (r = 0.59, p < 0.0001). Hc atrophy rate was not significantly correlated with any of the cognitive scales.

Conclusion

The lack of correlation between Hc atrophy and cognitive scales may reflect a combination of: the extensive functional damage to the Hc by the time AD is clinically established, the greater influence of ongoing cortical degeneration, and errors in Hc outlining. The strong correlations between brain atrophy and ventricular enlargement, and cognitive scales probably reflect the correspondence between these measures of overall cerebral loss and global cognitive measures in the moderate stages of AD.

Key words

Alzheimer's disease volumetric MRI measures cognitive scales clinical trials 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82:239–259PubMedCrossRefGoogle Scholar
  2. 2.
    Convit A, de Leon MJ, Golomb J, George AE, Tarshish CY, Bobinski M, Tsui W, De Santi S, Wegiel J, Wisniewski H (1993) Hippocampal atrophy in early Alzheimer’s disease: anatomic specificity and validation. Psychiatr Q 64:371–387PubMedCrossRefGoogle Scholar
  3. 3.
    Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRefGoogle Scholar
  4. 4.
    Foundas AL, Leonard CM, Mahoney SM, Agee OF, Heilman KM (1997) Atrophy of the hippocampus, parietal cortex, and insula in Alzheimer’s disease: a volumetric magnetic resonance imaging study. Neuropsychiatry Neuropsychol Behav Neurol 10:81–89PubMedGoogle Scholar
  5. 5.
    Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64:1563–1572PubMedCrossRefGoogle Scholar
  6. 6.
    Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN (2000) Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 57:339–344PubMedCrossRefGoogle Scholar
  7. 7.
    Fox NC, Scahill RI, Crum WR, Rossor MN (1999) Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 52:1687–1689PubMedGoogle Scholar
  8. 8.
    Freeborough PA, Fox NC (1997) The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans. Med Imaging 16:623–629CrossRefGoogle Scholar
  9. 9.
    Freeborough PA, Fox NC, Kitney RI (1997) Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed 53:15–25PubMedCrossRefGoogle Scholar
  10. 10.
    Freeborough PA, Woods RP, Fox NC (1996) Accurate registration of serial 3D MR brain images and its application to visualizing change in neurodegenerative disorders. J Comput Assist Tomogr 20:1012–1022PubMedCrossRefGoogle Scholar
  11. 11.
    Gauthier S, Gelinas I, Gauthier L (1997) Functional disability in Alzheimer’s disease. Int Psychogeriatr 9(Suppl 1):163–165PubMedCrossRefGoogle Scholar
  12. 12.
    Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM (10-5-2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553–1562PubMedCrossRefGoogle Scholar
  13. 13.
    Jack CR Jr, Petersen RC, O’Brien PC, Tangalos EG (1992) MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 42:183–188PubMedGoogle Scholar
  14. 14.
    Jack CR Jr, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, Tangalos EG, Kokmen E (1998) Rate of medial temporal lobe atrophy in typical aging and Alzheimer’s disease. Neurology 51:993–999PubMedGoogle Scholar
  15. 15.
    Jack CR Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, Xu Y, Shiung M, O’Brien PC, Cha R, Knopman D, Petersen RC (2003) MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 60:253–260PubMedCrossRefGoogle Scholar
  16. 16.
    Juottonen K, Laakso MP, Partanen K, Soininen H (1999) Comparative MR analysis of the entorhinal cortex and hippocampus in diagnosing Alzheimer disease. AJNR Am J Neuroradiol 20:139–144PubMedGoogle Scholar
  17. 17.
    Kesslak JP, Nalcioglu O, Cotman CW (1991) Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease. Neurology 41:51–54PubMedGoogle Scholar
  18. 18.
    Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F (1993) Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch Neurol 50:949–954PubMedGoogle Scholar
  19. 19.
    Mazziotta JC, Toga AW, Evans A, Fox P, Lancaster J (1995) A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). Neuroimage 2:89–101PubMedCrossRefGoogle Scholar
  20. 20.
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMedGoogle Scholar
  21. 21.
    Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43:2412–2414PubMedGoogle Scholar
  22. 22.
    Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46–54PubMedGoogle Scholar
  23. 23.
    Pasquier F, Richard F, Lebert F (2004) Natural history of frontotemporal dementia: comparison with Alzheimer’s disease. Dement Geriatr Cogn Disord 17:253–257PubMedCrossRefGoogle Scholar
  24. 24.
    Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141:1356–1364PubMedGoogle Scholar
  25. 25.
    Scahill RI, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC (2003) A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 60:989–994PubMedCrossRefGoogle Scholar
  26. 26.
    Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH (1997) Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl 2):S22–S32PubMedCrossRefGoogle Scholar
  27. 27.
    Seab JP, Jagust WJ, Wong ST, Roos MS, Reed BR, Budinger TF (1988) Quantitative NMR measurements of hippocampal atrophy in Alzheimer’s disease. Magn Reson Med 8:200–208PubMedCrossRefGoogle Scholar
  28. 28.
    Wang D, Chalk JB, Rose SE, de Zubicaray G, Cowin G, Galloway GJ, Barnes D, Spooner D, Doddrell DM, Semple J (2002) MR image-based measurement of rates of change in volumes of brain structures. Part II: application to a study of Alzheimer’s disease and normal aging. Magn Reson Imaging 20:41–48PubMedCrossRefGoogle Scholar
  29. 29.
    Whitwell JL, Crum WR, Watt HC, Fox NC (2001) Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. AJNR Am J Neuroradiol 22:1483–1489PubMedGoogle Scholar

Copyright information

© Steinkopff-Verlag 2008

Authors and Affiliations

  • B. H. Ridha
    • 1
  • V. M. Anderson
    • 1
  • J. Barnes
    • 1
  • R. G. Boyes
    • 1
  • S. L. Price
    • 1
  • M. N. Rossor
    • 1
  • J. L. Whitwell
    • 1
    • 4
  • L. Jenkins
    • 2
  • R. S. Black
    • 2
  • M. Grundman
    • 3
  • N. C. Fox
    • 1
  1. 1.Dementia Research Centre, Institute of NeurologyUniversity College LondonLondonUK
  2. 2.Wyeth PharmaceuticalsCollegevilleUSA
  3. 3.Elan Pharmaceuticals, Inc.CollegevilleUSA
  4. 4.Dept. of RadiologyMayo ClinicRochesterUSA

Personalised recommendations